HMDN

This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.

Asset Logo

Heramed Limited

πŸ‡¦πŸ‡Ί ASX

πŸ‘‘ Overview

πŸ“ˆ Performance

πŸ’΅ Cost

πŸ€“ Advanced

πŸ‘¨β€πŸ‘©β€πŸ‘§β€πŸ‘¦ Community

πŸ“ˆ

N/A
Annual Growth

5 years average annual growth

πŸ’΅

$ 500
Minimum Order

Due to regulatory requirements

🌏

3
Pearlers Invested

Since January 2020

πŸ‘‘ Overview

Key information
πŸ”Ž Fund Overview

Heramed Limited - Ordinary Fully Paid Deferred

πŸ“ˆ Performance

Price History

N/A

1M

All Time

Graph

Table

Unsure how much or often to invest?
πŸ—“οΈ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out β†’
πŸ’΅ Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out β†’
⏱️ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out β†’

πŸ’΅ Costs

πŸ’΅

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

πŸ’Ό

N/A
Management Fee

Included in unit price, not charged by Pearler

πŸ’Έ

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
πŸ’Έ Net fee calculator

πŸ€“ Advanced information

Technical Info

πŸ‘©β€πŸ‘©β€πŸ‘¦ Community Insights

How our community is investing

🌏 Pearlers invested in HMDN

0

πŸ“Š Total Capital Earnings

N/A

πŸ”ƒ Average investment frequency

N/A

πŸ’΅ Average investment amount

N/A

⏰ Last time a customer invested in HMDN

N/A
HMDN investor breakdown
πŸ’΅ Income of investors

More than 200k

150k - 200k

100k - 150k

50k - 100k

Less than 50k

πŸ‘Ά Age of investors

18 - 25

26 - 34

35 - 90

πŸ™‹ Legal gender of investors

Female

Male

Pearlers who invest in HMDN also invest in...

Heramed Limited

HMD

HeraMED Ltd. engages in the development and production of pregnancy monitoring solutions for home and professional use. The company offers hardware solutions supported by software applications. Its product HeraBEAT, is a medical-grade, clinically-validated and connected Ultrasound Fetal Doppler device predominantly for use by an expectant mother to self-monitor her fetus’ heart rate (FHR) at home. HeraBEAT communicates with any smartphone (iOS/Android) through Bluetooth Low Energy (BLE). A mother can hold or strap the HeraBEAT device to her abdomen, and the collected data is transmitted to her smartphone where the relevant readings are displayed through an interface. The firm also develops a service model which includes a homecare pregnancy solution. In addition, the Company develops artificial intelligence (AI), machine-learning, computerized algorithms to monitor and analyze the data so a healthcare professional or home user is informed of the wellbeing of the fetus.

πŸ™Œ Performance (5Yr p.a)

-15.71%

πŸ“Š Share price

$0.01 AUD

🩺 HEALTH CARE

Find Out More

VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.

πŸ™Œ Performance (5Yr p.a)

19.14%

πŸ“Š Share price

$134.81 AUD

🌏 GLOBAL

πŸ“ˆ HIGH PRICE GROWTH

⛳️ DIVERSIFIED

πŸ€– TECHNOLOGY

VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.

πŸ™Œ Performance (5Yr p.a)

7.32%

πŸ“Š Share price

$96.95 AUD

⛳️ DIVERSIFIED

πŸ‡¦πŸ‡Ί AUSTRALIA

πŸ’Έ FINANCIALS

🧱 MATERIALS

A200.AX was created on 2018-05-07 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The ETF currently has 6817.34m in AUM and 201 holdings. A200.AX aims to track the performance of an index (before fees and expenses) comprising 200 of the largest companies by market capitalisation listed on the ASX.

πŸ™Œ Performance (5Yr p.a)

8.07%

πŸ“Š Share price

$130.63 AUD

πŸ‡¦πŸ‡Ί AUSTRALIA

⛳️ DIVERSIFIED

πŸ’Έ FINANCIALS

πŸ“ˆ HIGH PRICE GROWTH

Magellan Financial Group Ltd. engages in the provision of funds management services. The company is headquartered in Sydney, New South Wales and currently employs 109 full-time employees. The company went IPO on 2004-07-01. The Company’s segments include Funds Management, Fund Investments and Associate Investments. The Funds Management segment provides investment fund management services to high net worth and retail investors in Australia and New Zealand, and to institutional investors globally. Its Funds Management activities include providing investment research and administrative services to certain clients; providing investment management and sub-advisory services under client mandates, and acting as responsible entity/trustee (RE) and/or investment manager (IM) for the funds (collectively the Magellan Funds). The Fund Investments segment comprises its direct investment in certain Magellan Funds and a select portfolio of listed Australian and international equities. The Associate Investments segment comprises a portfolio of selective investments in businesses in which it has a strategic interest.

πŸ™Œ Performance (5Yr p.a)

-16.39%

πŸ“Š Share price

$7.74 AUD

πŸ’° HIGH DIVIDEND

πŸ’Έ FINANCIALS

Want more shares? Try these...

πŸ“Š Share price

$0.00 AUD

HeraMED Ltd. engages in the development and production of pregnancy monitoring solutions for home and professional use. The company offers hardware solutions supported by software applications. Its product HeraBEAT, is a medical-grade, clinically-validated and connected Ultrasound Fetal Doppler device predominantly for use by an expectant mother to self-monitor her fetus’ heart rate (FHR) at home. HeraBEAT communicates with any smartphone (iOS/Android) through Bluetooth Low Energy (BLE). A mother can hold or strap the HeraBEAT device to her abdomen, and the collected data is transmitted to her smartphone where the relevant readings are displayed through an interface. The firm also develops a service model which includes a homecare pregnancy solution. In addition, the Company develops artificial intelligence (AI), machine-learning, computerized algorithms to monitor and analyze the data so a healthcare professional or home user is informed of the wellbeing of the fetus.

πŸ™Œ Performance (5Yr p.a)

-15.71%

πŸ“Š Share price

$0.01 AUD

🩺 HEALTH CARE